Comparative informativeness of various targeted panels in the genetic diagnosis of hypertrophic cardiomyopathy in children

Introduction. Hypertrophic cardiomyopathy (HCM) is the most common form of cardiomyopathy (CMP). Myocardial hypertrophy in children is associated with a large heterogeneous group of diseases with a high representation of non-sarcomeric causes. Purpose. The study compares diagnostic information from targeted next-generation sequencing (NGS) panels with different gene sets for HCM in children. Materials and methods. A molecular genetic study was conducted using two targeted panels (172 and 39 genes), followed by an assessment of their effectiveness. Results. The study included 53 children with HCM, the median age of which was 10 ± 3.5; 14.0 years. 13 children were examined using a large cardiac panel containing 172 genes. The remaining 40 patients were examined using a targeted panel for HCM containing 39 genes, while in 10 cases (25.0 %) genetic diagnostics was uninformative. Pathogenic and likely pathogenic variants in various genes were detected in 35 (66.0 %) patients. The informativeness of genetic diagnostics in the group of children under one year old was 60.7 %, in the group with onset at the age of over one year — 69.2 %. Conclusion. It is advisable to use an extended cardio panel for NGS for the purpose of genetic diagnosis of HCM in patients with the onset of the disease in the first year of life and small target panels for HCM in patients with the onset at an older age.

1. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503–3626. DOI:10.1093/eurheartj/ehad194.

2. Lipshultz SE, Orav EJ, Wilkinson JD, et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet. 2013;382(9908):1889– 1897. DOI:10.1016/S0140-6736(13)61685-2.

3. Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249–54. DOI:10.1016/j.jacc.2015.01.019.

4. Stegeman R, Paauw ND, de Graaf R, et al. The etiology of cardiac hypertrophy in infants. Sci Rep. 2021;11(1):10626. 5. Chan W, Yang S, Wang J, et al. Clinical characteristics and survival of children with hypertrophic cardiomyopathy in China: A multicentre retrospective cohort study. EClinicalMedicine. 2022;49:101466.

5. Núñez L, Gimeno-Blanes JR, Rodríguez-García MI, et al. Somatic MYH7, MYBPC3, TPM1, TNNT2 and TNNI3 mutations in sporadic hypertrophic cardiomyopathy. Circ J. 2013;77(9):2358–65. DOI: 10.1253/circj.cj-13-0294.

6. Allouba M, Walsh R, Afify A, et al. Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy. Eur Heart J. 2023 Dec 21;44(48):5146– 5158.

7. Vogiatzi G, Lazaros G, Oikonomou E, et al. Role of genetic testing in cardiomyopathies: a primer for cardiologists. World J Cardiol. 2022 ;26 14(1):29–39.

8. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424. DOI:10.1038/gim.2015.30.

9. Marston NA, Han L, Olivotto I, et al. Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Eur Heart J. 2021;42(20):1988–1996. DOI:10.1093/eurheartj/ehab148.

10. Rubattu S, Bozzao C, Pennacchini E, et al. A nextgeneration sequencing approach to identify gene mutations in early- and late-onset hypertrophic cardiomyopathy patients of an italian cohort. Int J Mol Sci. 2016;17(8):1239. DOI:10.3390/ijms17081239.

11. Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17(11):880– 8. DOI:10.1038/gim.2014.205.

12. Andersen PS, Havndrup O, Hougs L, et al. Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives. Hum Mutat. 2009;30(3):363–370. DOI:10.1002/humu.20862.

13. Erdmann J, Daehmlow S, Wischke S, et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet. 2003;64:339–349. 15. Lorenzini M, Norrish G, Field E, et al. Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers. J Am Coll Cardiol. 2020 Aug 4;76(5):550–559. DOI:10.1016/j.jacc.2020.06.011.

14. Alexander PMA, Nugent AW, Daubeney PEF, et al. On behalf of the National Australian Childhood Cardiomyopathy Study. Long-term outcomes of hypertrophic cardiomyopathy diagnosed during childhood: results from a national population-based study. Circulation. 2018;138:29– 36. DOI:10.1161/CIRCULATIONAHA.117.028895.

15. Norrish G, Field E, McLeod K, et al. Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom. Eur Heart J. 2019;40:986–993. DOI:10.1093/eurheartj/ehy798.

16. Boleti O, Norrish G, Field E, et al. Natural history and outcomes in paediatric RASopathyassociated hypertrophic cardiomyopathy. ESC Heart Fail. 2024;11(2):923–936. DOI:10.1002/ehf2.14637.

17. Cecconi M, Parodi MI, Formisano F, et al. Targeted next-generation sequencing helps to decipher the genetic and phenotypic heterogeneity of hypertrophic cardiomyopathy. Int J Mol Med. 2016;38(4):1111–24. DOI:10.3892/ijmm.2016.2732.

18. Thomson KL, Ormondroyd E, Harper AR, et al. Analysis of 51 proposed hypertrophic cardiomyopathy genes from genome sequencing data in sarcomere negative cases has negligible diagnostic yield. Genet Med. 2019;21(7):1576–84. DOI:10.1038/s41436-018-0375-z.

19. Aljeaid D, Sanchez AI, Wakefield E, et al. Prevalence of pathogenic and likely pathogenic variants in the RASopathy genes in patients who have had panel testing for cardiomyopathy. Am J Med Genet A. 2019;179(4):608– 14. DOI:10.1002/ajmg.a.61072.

20. Hathaway J, Krista Heliö K, Saarinen I, et al. Diagnostic yield of genetic testing in a heterogeneous cohort of 1376 HCM patients. BMC Cardiovascular Disorders. (2021) 21:126doi: 10.1186/s12872-021-01927-5

21. Teekakirikul P, Zhu W, Huang HC, et al. Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Biomolecules. 2019;9(12):878. DOI:10.3390/biom9120878.

22. Ceyhan-Birsoy O, Miatkowski MM, Hynes E, et al. NGS testing for cardiomyopathy: utility of adding RASopathy-associated genes. Hum Mutat. 2018;39(7):954– 8. DOI:10.1002/humu.2.

23. Gal DB, Morales A, Rojahn S, et al. Comprehensive Genetic Testing for Pediatric Hypertrophic Cardiomyopathy Reveals Clinical Management Opportunities and Syndromic Conditions. Pediatr Cardiol. 2022;43(3):616–623. DOI:10.1007/s00246-021-02764-1.